Savara announces EAP for molgramostim for patients with aPAP

Savara announced the Savara Early Access Program, a molgramostim Expanded Access Program, EAP, for patients with Autoimmune Pulmonary Alveolar Proteinosis, aPAP. The program enables physicians to request molgramostim for eligible aPAP patients in select geographies where the product is not commercially available and in compliance with local regulatory requirements. “Expanded access is granted to investigational products that address a serious condition for which there are no comparable therapies available,” said Matt Pauls, Chair and CEO of Savara. “Given the high unmet need in aPAP, and positive results demonstrated in the Phase 3 IMPALA-2 clinical trial, we felt it was critically important to establish the Savara Early Access Program to allow eligible aPAP patients pre-approval access to molgramostim. This program reflects our ongoing commitment to the global aPAP community and the goal of potentially delivering an effective therapy for patients with this rare lung disease as quickly as possible.”